Passionate about driving creative innovation for unmet medical needs, prioritizing patients. We have decades of pharmaceutical R&D experience devoted to improving therapies.
In Kiran we are now leveraging on:
- AvidinOX®, a clinically tested proprietary delivery platform, able to act as an artificial receptor for any biotinylated moiety including radionuclides, antibodies and cells
- Proprietary human antibodies not yet patented (i.e. ErbB3 and PDL1)
- Proprietary phage display libraries of human antibodies obtained from normal and diseased subjects
- Proprietary phage display libraries of peptides, constrained peptides and protein domains